CN101870978A - Clostridium difficile exotoxin A carboxy-terminal gene sequence with optimized codon and nucleic acid vaccine thereof - Google Patents

Abstract

The invention belongs to the technical field of biomedicine, relating to a clostridium difficile exotoxin A carboxy-terminal gene sequence with optimized codon and a nucleic acid vaccine thereof. The codon optimized gene sequence gives consideration to use preferences of mammalian cells and Esherichia coli codon, and the related clostridium difficile vaccine is composed of exotoxin A carboxy-terminal gene sequence with optimized codon and eukaryon expression vector pJW4303. The clostridium difficile exotoxin A carboxy-terminal gene segment optimized by codon can not only be used for constructing nucleic acid vaccines, effectively stimulating host immune system after immunizing mammals, generating better humoral immunity reaction, being applicable to conduct pronucleus expression in esherichia coli, and laying a foundation for acquiring protein in great quantities.

Description

Codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence and nucleic acid vaccine thereof

Technical field

The invention belongs to the biological medicine technology field, relate to codon optimized clostridium difficile exotoxin A carboxy-terminal gene fragment and nucleic acid vaccine thereof.

Background technology

Clostridium difficile is a kind of Gram-positive, the bacillus fusiformis of brood cell, obligate anaerobic is arranged.Current, the prevention of C. difficile infection, diagnosis, treatment are faced with numerous difficulties.On the one hand, clostridium difficile extensively is present in the institute in the environment, and can tolerate sterilizing agent commonly used in the multiple institute as the brood cell of its dormancy form, and it has become the main pathogens of the ward infection diarrhoea that is only second to Campylobacter; Metronidazole, vancomycin, as two kinds of main medicines of treatment C. difficile infection, their resistance is also constantly being accumulated, is being propagated, and curative effect reduces day by day, and for the treatment of recurrent cases, these two kinds of medicines present incompetent state.In addition on the one hand, up to the present, still do not have effective, commercial vaccine and come out; ELISA detection kit based on toxin costs an arm and a leg, and is difficult to clostridium difficile is carried out routine clinical detection, also is not suitable for large-scale epidemiology survey and long term monitoring; Therapeutic antibodies is as a kind of safe, effective, cheap microbiotic substitute, and having a bright future but still is in probe phase.So, be badly in need of exploitation safety, effectively, convenient, cheap clostridium difficile vaccine protects the high risk population; Simultaneously, strive on the basis of vaccine the corresponding monoclonal antibody of exploitation, for diagnostic reagent and therapeutic antibodies are laid solid foundation.

Clostridium difficile enters digestive tube by fecal-oral route, secrete extracellular toxin then and cause diarrhoea.Wherein, toxin A is a kind of enterotoxin, is again a kind of cytotoxin, is the morbific main virulence factor of clostridium difficile.Discover, the clostridium difficile exotoxin A have only when its carboxyl terminal with can bring into play toxic action after the target cell surface receptor combines; The molecular surface structure of clostridium difficile exotoxin A is most of to be covered by its carboxyl terminal; At the antibody of clostridium difficile exotoxin A carboxy-terminal, can effectively suppress its intestines toxicity and cytotoxicity, have protective effect.So clostridium difficile exotoxin A carboxy-terminal is the ideal structure territory of vaccine research and antibody exploitation.

Nucleic acid vaccine (nucleic vaccine), have another name called gene vaccine (gene vaccine) or dna vaccination (DNAvaccine), its essence is that the carrier for expression of eukaryon that contains antigen gene is imported into and is absorbed by zooblast behind the animal body and express corresponding antigen albumen, thereby induces body to this proteic immune response.As emerging in recent years a kind of vaccine, it is attracting people with its unique advantage: (1) antigen is synthetic similar to the natural infection of pathogenic agent with the submission process, by MHC I class and the direct submission immunity system of II quasi-molecule.The particularly immune response of inducing producing specificity CD8+ lymphocyte (CTL), this be inactivated vaccine and subunit vaccine can not compare; (2) immunogenic unicity.Have only the antigen gene on the carrier to obtain expressing in cell, itself does not have antigenicity carrier.And the virus live vector vaccine of reorganization also has the many albumen of himself to obtain expressing except destination gene expression; (3) be easy to make up and prepare, good stability, with low cost, be suitable for scale operation.But the goal gene overwhelming majority who is used for making up nucleic acid vaccine at present comes from prokaryotic organism such as virus or bacterium, and the research of vaccine and application are mainly eukaryote, as mouse, and senior Mammalss such as the macaque or the mankind.Because prokaryotic organism and eukaryote are used on the preference at codon and there are differences; the foreign gene that causes being used for making up nucleic acid vaccine can not effective expression in the mammalian hosts body, therefore just effectively the immunity system of stimulation of host produce immanoprotection action preferably.This is to cause the lower major cause of present nucleic acid vaccine immunity originality.

Summary of the invention

The objective of the invention is to overcome above-mentioned defective, a kind of codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence is provided.

Another object of the present invention provides a kind of clostridium difficile extracellular toxin nucleic acid vaccine that is made up by said gene.

Purpose of the present invention is achieved through the following technical solutions:

A kind of codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence, sequence are SEQ ID NO.1

A kind of clostridium difficile extracellular toxin nucleic acid vaccine is that clostridium difficile exotoxin A carboxy-terminal gene sequence and the carrier for expression of eukaryon of SEQ ID NO.1 formed by sequence.

Described carrier for expression of eukaryon is pJW4303.

The construction step of codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence provided by the invention and nucleic acid vaccine thereof is as follows:

(1) design of codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence and synthetic

At first choose 978 base sequences in clostridium difficile exotoxin A gene carboxyl terminal end, use the gene order of software MacVector 7.2 analysis of encoding then, find out its codon and use preference to find out with Mammals codon use preference simultaneously, use the different codon site of preference with e. coli codon.Use the identical codon of preference for Mammals with intestinal bacteria, with Mammals and intestinal bacteria all the codon of preference substitute and use the different codon of preference in the clostridium difficile exotoxin A gene, design codon optimized clostridium difficile exotoxin A carboxy-terminal sequence then, and obtained codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence through the chemosynthesis of genome company.The protein amino acid sequence that codon optimized sequence is coded and original aminoacid sequence are consistent.For example: the triplet codon of coding Isoleucine Ile mainly is ATT in the clostridium difficile exotoxin A gene, and in senior mammalian genes groups such as the mankind, mouse, mainly be ATC, in intestinal bacteria, mainly be ATC also, when codon optimized, can select all codon ATC of preference of mammalian cell and intestinal bacteria for use.Clostridium difficile exotoxin A carboxy-terminal gene sequence after the optimization is SEQ IDNO.1, and the sequence before optimizing is SEQ ID NO.2.

(2) the recombinant vectors pMK-RQ-TcdA-C that contains target sequence that genome company is provided carries out enzyme and cuts, reclaim test kit (TaKaRa Agarose Gel DNA Purification Kit Ver.2.0 with dna gel, the precious biotech firm in Dalian) the purpose fragment of recovery purifying 995bp, this fragment is for be connected with the gene order of Pst I and BamH I restriction enzyme site respectively at codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence (TcdA-C) two ends, so that the structure of nucleic acid vaccine.

(3) gene fragment clone that step (2) is obtained obtains recombinant plasmid pJW4303-TcdA-C in carrier for expression of eukaryon pJW4303.After reorganization plasmid extraction, enzyme are cut, checked order, determine to have obtained plasmid in line.

Beneficial effect of the present invention:

Compare with wild type gene, the codon frequency of occurrences of the codon of mammalian cell preference and intestinal bacteria preference increases in the codon optimized gene, but the clostridium difficile exotoxin A carboxy-terminal aminoacid sequence of its coding is constant, thereby makes it be more suitable for protein expression in mammalian cell and intestinal bacteria.

Because there is the preference of codon in the nature biotechnology body; in the heterologous host body, be difficult to effective expression from the clostridium difficile exotoxin A carboxy-terminal gene clone in pathogenic agent source; therefore the effective immunity system of stimulation of host just makes it to produce immanoprotection action preferably.In order to improve the expression efficiency of heterologous gene in Mammals and intestinal bacteria, often need nucleotide coding sequence is optimized.Because the optimization to nucleotide sequence does not still have unified standard or principle at present.Therefore at aminoacid sequence, different researchists can design expression and the manufacturing that different nucleotide sequences is used for target polypeptides fully, and correspondingly expression efficiency also may there are differences.Nucleotide coding sequence according to we optimize has overcome above-mentioned defective, has improved the clostridium difficile exotoxin A carboxy-terminal protein expression level.And the gene after will optimizing is used to make up nucleic acid vaccine, can stimulate host's immunity system behind immune Mammals effectively, has produced humoral immune reaction preferably.

The contriver directly is cloned into carrier for expression of eukaryon with the clostridium difficile exotoxin A carboxy-terminal gene of codon optimization, made up clostridium difficile nucleic acid vaccine pJW4303-TcdA-C, this vaccine can be in eukaryotic cell 293T cell effective expression, immune animal can stimulate and produces specific antibody.

Description of drawings

The codon preference comparative result A of Fig. 1 wild-type and codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence is the comparison (index＞1 is mammalian cell institute preference) in the mammalian cell expression preference of wild-type and codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence, ordinate zou is represented the preference index, and X-coordinate is represented the nucleotides sequence column position.Left side figure is the wild-type clostridium difficile exotoxin A carboxy-terminal gene sequence, and right figure is codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence.

B is the comparison (index＞1 is intestinal bacteria institute preference) in the escherichia coli expression preference of wild-type and codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence, and ordinate zou is represented the preference index, and X-coordinate is represented the nucleotides sequence column position.Left side figure is the wild-type clostridium difficile exotoxin A carboxy-terminal gene sequence, and right figure is codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence.

The enzyme of Fig. 2 plasmid pJW4303-TcdA-C is cut the result

M; Marker; 1～3 swimming lane is respectively first clone who is selected and cuts without enzyme, through BamH I single endonuclease digestion, through the electrophorogram of Pst I and BamH I double digestion; All the other and the like be respectively the 2nd, 3,4,5 clone and cut without enzyme, through BamH I single endonuclease digestion, through the electrophorogram of Pst I and BamHI double digestion.

The Western blot analytical results of the 293T cell target protein expression of Fig. 3 transfection pJW4303-TcdA-C

1:pJW4303-TcdA-C transfection lysate; 2:pJW4303-TcdA-C transfection supernatant; 3:pJW4303 transfection lysate; 4:pJW4303 transfection supernatant.Antigen is the culture supernatant or the lysate of pJW4303 empty carrier, pJW4303-TcdA-C transfection 293T cell, and used antiserum(antisera) is an immunize rabbit serum, and extent of dilution is 1: 500.

IgG antibody response time curve after Fig. 4 pJW4303, the pJW4303-TcdA immunity New Zealand white rabbit

R116, R117 are the New Zealand white rabbit of pJW4303-TcdA-C immunity, and R61, R62 are the New Zealand white rabbit of pJW4303 immunity.Arrow is represented immune time point.

Western blot analytical results after Fig. 5 pJW4303-TcdA-C immunity New Zealand white rabbit

1:pJW4303-TcdA-C transfection lysate; 2:pJW4303-TcdA-C transfection supernatant; 3:pJW4303 transfection lysate; 4:pJW4303 transfection supernatant.Used one anti-is immunize rabbit serum, and extent of dilution is 1: 500.

Embodiment

The design of the clostridium difficile exotoxin A carboxy-terminal gene sequence that embodiment 1. is codon optimized is with synthetic

At first use software MacVector 7.2 analysis of encoding clostridium difficile exotoxin A carboxy-terminal gene sequences, find out its codon and use preference and use the different site of preference with Mammals, e. coli codon.For using the different codon site of preference, usefulness mammalian cell and the intestinal bacteria all codon of preference substitute, and design codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence.The above-mentioned codon optimized coded protein amino acid sequence consensus amino acid sequence original of gene order with it.Hand over U.S. GENEART company synthetic the sequence that designs, the carrier pMK-RQ that packs into is built into recombinant plasmid pMK-RQ-TcdA-C.Confirm that through order-checking the synthetic sequence is correct.

To carry out codon optimized site in order clearly showing, now TcdA-C nucleotide sequence after codon optimized and codon optimized preceding TcdA-C nucleotide sequence to be compared.Comparative result following (* is a terminator codon):

ATG ATT AAA TTA AAA TTT GGT GTT TTT TTT ACA GTT TTA CTA TCT TCA GCA TAT before optimizing

Optimize back ATG AT CAA G CT GAAA TT CGG CGT GTT CTT CAC CGT G CT GCT G AGCTC CGCC TA C

Amino acid M I K L K F G V F F T V L L S S A Y

GCA CAT GGA ACA CCT CAA AAT ATT ACT GAT TTG TGT GCA GAA TAC CAC AAC ACA before optimizing

Optimize back GC CCA CGG CAC CCC GCA GAA CAT CAC CGA C CTG TG CGC CGA GTAC CAC AAC AC C

Amino acid A H G T P Q N I T D L C A E Y H N T

CAA ATA CAT ACG CTA AAT GAT AAG ATA TTT TCG TAT ACA GAA TCT CTA GCT GGA before optimizing

Optimize back CA GAT CCA CAC CCT GAA CGA CAA AAT CTT CTC CTA CAC CGA GTC CCT GGC GGG C

Amino acid Q I H T L N D K I F S Y T E S L A G

AAA AGA GAG ATG GCT ATC ATT ACT TTT AAG AAT GGT GCA ACT TTT CAA GTA GAA before optimizing

Optimize back AA G CG CGAG ATG GC CATC AT CAC CTT CAAG AA CGG CGC GAC CTT CCA GGT GGA G

Amino acid K R E M A I I T F K N G A T F Q V E

GTA CCA GGT AGT CAA CAT ATA GAT TCA CAA AAA AAA GCG ATT GAA AGG ATG AAG before optimizing

Optimize back GT GCC GGG CAG CCA GCA CAT CGA CTC CCA GAA GAAA GC CAT CGA G CG CATG AAG

Amino acid V P G S Q H I D S Q K K A I E R M K

GAT ACC CTG AGG ATT GCA TAT CTT ACT GAA GCT AAA GTC GAA AAG TTA TGT GTA before optimizing

Optimize back GA CACC CTG CG CAT CGC CTA CCT GAC CGA GGC CAA GGT GGA GAAG CT GTG CGT G

Amino acid D T L R I A Y L T E A K V E K L C V

TGG AAT AAT AAA ACG CCT CAT GCG ATT GCC GCA ATT AGT ATG GCA AAT TAA before optimizing

Optimize back TGG AA CAA CAA GAC CCC GCA CGC CAT CGC GGC CAT CAG CATG GC GAA CTAA

Amino acid W N N K T P H A I A A I S M A N *

Preference has relatively taken place and has sexually revised in above-mentioned codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence and wild-type.Software MacVector 7.2 analog results of Fig. 1 as can be seen, compare with wild type gene, the codon frequency of occurrences of the codon of mammalian cell preference and intestinal bacteria preference increases in the codon optimized gene, but their coded aminoacid sequences are constant, thereby make it be more suitable for protein expression in mammalian cell and intestinal bacteria.

The structure of embodiment 2. carrier for expression of eukaryon pJW4303-TcdA-C

(1) TcdA-C fragment, the linear big segmental acquisition of plasmid pJW4303: use Pst I and BamH I double digestion plasmid pJW4303 and pMK-RQ-TcdA-C (synthetic) respectively by U.S. GENEART company.The endonuclease reaction system is: 10 * BufferTango ^TM4 μ l, plasmid (pJW4303, pMK-RQ-TcdA-C) 10 μ l, Pst I 1.5 μ l, BamH I 1.5 μ l, moisturizing to 40 μ l, 37 ℃, 2h.

(2) enzyme is cut product purification: above-mentioned enzyme is cut product behind the agarose gel electrophoresis of 10g/L, place under the Ultraviolet Detector, reclaim test kit (Agarose Gel DNA Purification Kit Ver.2.0 according to gel, the precious biotech firm in Dalian) specification sheets, cutting-out contains the segmental gel of purpose, analytical balance claims the quality of blob of viscose, presses the volume that 1mg=1 μ l calculates blob of viscose.Add the DR-I Buffer of 4 times of volumes, place 75 ℃ of water-bath heating and melting blob of viscoses, be interrupted vibration and mix, melt fully, add the DR-II Buffer of DR-I Buffer 1/2 volume, fully mixing solution until blob of viscose.Centrifugal adsorption column is placed on the collection tube, shifts mixing solutions to adsorption column, 12000rpm, centrifugal 1min.Abandon filtrate, add 500 μ l Rinse A liquid, 12000rpm, centrifugal 30s.Abandon filtrate, add 700 μ l Rinse B liquid, 12000rpm, centrifugal 30s, repeated washing are once.Adsorption column is placed on the new Ep pipe, and the film central authorities dropping 25 μ l sterile purified waters at adsorption column leave standstill 60s.12000rpm, centrifugal 1min, the elutriant in the Ep pipe is target DNA solution at this moment.Measure the concentration of dna solution, with 10g/L agarose gel electrophoresis analysis rubber tapping purification effect, elutriant is kept in-20 ℃ of refrigerators standby.

(3) ligation: with the T4DNA ligase enzyme purpose fragment is connected with the linear big fragment of plasmid pJW4303, obtains the pJW4303-TcdA-C recombinant expression plasmid, be the nucleic acid vaccine of clostridium difficile exotoxin A provided by the present invention.The ligation system is: 10 * T4 DNA Ligase Buffer, 1 μ l, and linearizing pJW4303 1 μ l, the purpose fragment 7 μ l of purifying, T4 DNA Ligase 1 μ l, mixing is placed 16h for 16 ℃.Connector transforms the HB101 competent cell.

The evaluation of embodiment 3. recombinant plasmid pJW4303-TcdA-C

3.1 pJW4303-TcdA-C transforms the HB101 competent cell respectively

1) 10 μ l connectors is joined in the Ep pipe that 100 μ l HB101 competent cells are housed the tube wall several of flapping gently, abundant mixing, ice bath 30min.

2) the Ep pipe is placed 42 ℃ of water-bath 90s.

3) in the Ep pipe, slowly add LB substratum 0.5mL, 37 ℃, 80rpm, jolting 45min.

4) bacterium liquid is coated on the LB flat board that contains penbritin (0.1g/L), 37 ℃, overnight incubation.

3.2 screening positive clone

5 single bacterium colonies of picking are inoculated in respectively in 5 culture test tubes (the LB substratum that contains the 0.1g/L penbritin) at random, and 37 ℃, 200rpm jolting, overnight incubation.

3.3 extract recombinant plasmid pJW4303-TcdA-C (plasmid extracts test kit in a small amount: TaKaRa MiniBEST PlasmidPurification Kit Ver.2.0, TaKaRa company) in a small amount

1) slowly be drawn onto in aseptic super clean bench in the 1.5ml centrifuge tube shaking the bacterium that spends the night in 3.2, remaining a small amount of bacterium liquid is stored in 4 ℃ in the culture test tube.

2) bacterium liquid in the centrifuge tube, the centrifugal 2min of 12000rpm abandons supernatant under the normal temperature.

3) add the 250 μ l Solution I bacterial precipitation that fully suspends.

4) add 250 μ l Solution II, gentleness is put upside down 5-6 time, forms clear solution.

5) the Solution III of 4 ℃ of precoolings of adding 400 μ l, gentleness is put upside down 5-6 time, and room temperature leaves standstill 2min then.

6) room temperature 12000rpm, centrifugal 10min.

7) Spin Column is placed on the Collection Tube, with 6) in supernatant liquor join among the Spin Column, the centrifugal 1min of 12000rpm abandons filtrate.

8) 500 μ l Rinse A are added among the Spin Column, the centrifugal 30s of 12000rpm abandons filtrate.

9) 700 μ l Rinse B are added among the Spin Column, the centrifugal 30s of 12000rpm abandons filtrate.

10) repeating step 9.

11) Spin Column is placed on the 1.5mlEp, at the sterile purified water of the dropping 60 μ l of film central authorities, room temperature leaves standstill 1min

12) the centrifugal 1min of 12000rpm, elutriant is the solution that contains plasmid.

3.4 cutting, enzyme identifies plasmid pJW4303-TcdA-C

Plasmid pJW4303-TcdA-C BamH I single endonuclease digestion, Pst I and BamH I double digestion.Single endonuclease digestion reaction system (10 μ l): 10 * Buffer Tango ^TM1 μ l, plasmid (0.22mg/mL) 2 μ l, BamH I 0.5 μ l, moisturizing to 10 μ l.Double digestion reaction system (10 μ l): 10 * Buffer Tango ^TM1 μ l, plasmid (0.22mg/mL) 2 μ l, Pst I 0.25 μ l, BamH I 0.25 μ l, moisturizing to 10 μ l.Hatch 2h for 37 ℃.Add 1 μ l, 10 * Loading buffer and stop endonuclease reaction.10g/L agarose gel electrophoresis observations, enzyme are cut the rear electrophoresis collection of illustrative plates and are seen Fig. 2, and Fig. 2 shows that 5 clones all make up correctly.Enzyme is cut the correct bacterium of evaluation serve the order-checking of Hai Yingjun company, the correct bacterium of checking order is drawn flat board three times, and optional wherein two mono-clonal bacteriums preserve.

A large amount of preparations of embodiment 4. plasmid pJW4303-TcdA-C (the big extraction reagent kit of plasmid is QIAGEN Plasmid Mega Kit (5), Qiagen company)

1) absorption identifies that correct bacterium preservation liquid 5 μ l are inoculated in 5ml and contain in the LB nutrient solution of penbritin, 37 ℃, and 200rpm, overnight growth.

2) by 1: 500 with 1) in cultivate bacterium liquid and be inoculated in 1000ml and contain in the LB nutrient solution of penbritin, 37 ℃, 200rpm, overnight growth.

3) bacterium moved on in the 250ml centrifugal bottle in second day, 4 ℃, the centrifugal 15min of 6000g abandon supernatant, collect bacterium.

4) add 50ml damping fluid P1, jolting repeatedly all is resuspended in the solution bacterium.

5) add 50ml damping fluid P2, gentleness is put upside down 5-6 time, and solution is even blueness, leaves standstill 5min.

6) add 50ml damping fluid P3, gentleness is put upside down 5-6 time, and blue solution disappears, the solution layering, and the upper strata is blocky oyster white agglomerate, lower floor is limpid liquid, places 30min on ice.

7) 4 ℃, 21000g, centrifugal 30min,

8) supernatant is transferred to another centrifugal bottle, 4 ℃, 21000g, centrifugal 15min.

9) in adsorption column, add QBT damping fluid 35ml equilibrium adsorption post.

10) supernatant that obtains in the step 8 is added in the adsorption column, filters, abandon filtrate.

11) add lavation buffer solution QC 200ml, cross post, abandon filtrate.

12) add elution buffer QF 35ml, cross post, collect filtrate.

13) in collecting liquid, add the 24.5ml Virahol, 4 ℃, 16000g, centrifugal 30min abandons supernatant.

14) add 7ml 70% ethanol, the centrifugal 10min of normal temperature 16000g abandons supernatant.

14) will there be sedimentary centrifuge tube to dry naturally, use 1ml physiological saline solution plasmid agglomerate then in super clean bench.

15) (wavelength 260nm～280nm) measures plasmid concentration and 260/280 ratio in the extracting gained solution to ultraviolet spectrophotometry.

Embodiment 5. cell transfectings

The 293T cell is with containing two DMEM high glucose mediums that resist 10% foetal calf serums at 37 ℃, 5%CO ₂Be cultured to logarithmic phase in the saturated humidity incubator, after the 2.5g/L trysinization, with 5.0 * 10 ⁶Individual cell (6mL) is inoculated in the 10cm culture dish, when waiting to grow to 80% fusion, carries out cell transfecting according to the PEI infection protocol.Get PEI 75 μ l, pJW4303-TcdA-C 15 μ g add and contain two anti-DMEM high glucose medium to 825 μ l, abundant mixing, incubated at room 15min is added to above-mentioned mixed solution then in the culture dish and shakes gently to make and mixes, simultaneously with pJW4303 empty plasmid transfectional cell as negative control.Replacing does not contain serum and contains two anti-DMEM nutrient solutions behind the 8h.Gather in the crops culture supernatant and cell pyrolysis liquid after continuing to cultivate 48h, carry out Western blot and analyze.Analytical results as shown in Figure 3.Can detect the expression of specific proteins among Fig. 3 behind the demonstration pJW4303-TcdA-C transfection 293T cell in supernatant and cell pyrolysis liquid, its apparent molecular weight is about 36kDa.The existence that the supernatant of negative control empty carrier pJW4303 transfection 293T cell and lysate do not detect specific proteins.Western blot analysis revealed, the pJW4303-TcdA-C nucleic acid vaccine can be in 293T cell inner expression corresponding proteins.The nucleic acid vaccine of explanation after codon optimized can be in host cell expressing protein.

Transfectional cell results: draw cell conditioned medium liquid, 2500rpm, room temperature, centrifugal 10min, it is ℃ frozen to draw supernatant-20.(concentration 10mM is pH7.2) with cell wash-out from culture dish, collecting cell suspension with PBS, 2500rpm, room temperature, centrifugal 10min, abandon supernatant, add lysate (50mM Tris-HCl PH7.6,150mM NaCl, 1%Triton faces with preceding adding 2%100mM PMSF (phenylmethylsulfonyl fluoride)), hatch 15min on ice, 12000rpm, 4 ℃, centrifugal 60min, collect supernatant liquor ,-20 ℃ frozen.

The research of embodiment 6. codon optimized pJW4303-TcdA-C nucleic acid vaccine immunity originality

After nucleic acid vaccine makes up and expresses successfully, experimental animal is carried out immunity, detect the immunogenicity of codon optimized clostridium difficile extracellular toxin nucleic acid vaccine by ELISA and Western blot method.

6.1pJW4303-TcdA-C immune New Zealand white rabbit, experimental design sees Table 1:

Table 1

Group	Quantity (only)	Nucleic acid vaccine	Dosage
				??A	??2	Empty carrier pJW4303	??200μg
??B	??2	??pJW4303-TcdA-C	??200μg

With empty carrier pJW4303 and each immune one group of new zealand rabbit of pJW4303-TcdA-C.Intramuscular injection, the immunity of live body gene lead-in mode, guarantee syringe needle depth of penetration 2mm, carry out (the technical parameter: voltage 100V of electrotransfection in the body in the injection site with WJ-2002 live body gene introducing apparatus immediately after the injection, positive and negative each 6 times of pulse number, the wide 60ms of ripple, frequency 60Hz), it is effective to be considered as electrotransfection with rabbit leg muscle generation shake.Carry out dna immunization in the 0th, 2,4,8 weeks, two weeks blood sampling before each immunity and after the last immunity.

6.2ELISA TcdA-C specific IgG in the detection serum

Detect special IgG antibody response in the serum with the ELISA method, estimate the pJW4303-TcdA-C nucleic acid vaccine and in Rabbit Model, induce the ability that produces humoral immunization.

1) pJW4303-TcdA-C transfection product is as antigen coated elisa plate (using PBS pH7.2-7.4 as coating buffer, the dilution in 1: 5 of transfection supernatant, transfection cracking dilution in 1: 10), and every hole 100 μ l, spend the night by 4 ℃.

2) abandon coating buffer, wash plate 5 times (PBST constitutes 10mMPBS and 0.05%Tween-20) with 1XPBST.

3) 5% skim-milk (PBS, 0.05%Tween-20,5% skim-milk) is 37 ℃, sealing 1h, every hole 200 μ l.

4) abandon confining liquid, wash plate 5 times with 1XPBST.

5) one anti-is serum to be detected, and extent of dilution is 1: 500.Every hole adds 100 μ l, 37 ℃, hatch 1h (an anti-diluent: 4% whey-protein, 0.5%Tween-20, PBS).

6) abandon one and resist, wash plate 5 times with 1XPBST.

7) two anti-are the goat anti-rabbit igg of HRP mark, and extent of dilution is 1: 5000, and every hole adds 100 μ l, 37 ℃, hatches 1h.(two anti-diluents: 4% whey-protein, 0.5%Tween-20, PBS).

8) abandon two and resist, wash plate 5 times with 1XPBST.

9) TMB colour developing (TMB solution formula: 1 in TMB tablet, 0.1M phosphoric acid citrate buffer (the pH value is 5.0) 5ml, distilled water 5ml, 30% hydrogen peroxide, 2 μ l), every hole adds 100 μ l, room temperature, 3.5min, every hole adds the H of 50 μ l1M ₂SO ₄Color development stopping.

10) each hole A450 value is measured and write down to microplate reader, calculates multiple hole mean value, and as the cut-off value, and immune metapore OD value is less than 0.05 also removal with 2.1 times of preimmune serum OD value.

New Zealand white rabbit serum T cdA-C specific IgG antibodies answering time curve as shown in Figure 4.Show pJW4303-TcdA-C dna vaccination and pJW4303 empty carrier 2 new zealand rabbits of immunity respectively among the figure, in 0,2, the immunity of 4,8 weeks, 2 weeks of before the immunity and immunity back are collected serum.For the first time all can detect the TcdA-C specific IgG in 2 rabbit serum of immunity back 2 all pJW4303-TcdA-C dna vaccination groups, and along with the increase of immune time, immune response strength improves.But the serum of 2 pJW4303 empty carrier immune rabbits does not detect antibody response.Arrow is represented immune time point.

6.3Western blot detects specific IgG in the serum

1) each 20 μ l of pJW4303-TcdA-C transfection 293T lysis and supernatant, pJW4303 transfection 293T lysis and supernatant add 5x sample-loading buffer 5 μ l, 100 ℃, boil 10min.

2) separation gel (7.5ml 30% acrylamide soln, 3.7ml 1MTris/Cl pH8.8,150 μ l 10%SDS, 150 μ l, 10% ammonium persulfate, 6 μ l TEMED) of preparation 15%, encapsulating, liquid level top Jia Shui, polymerization 20～30min under the room temperature.

3) abandon water, the spacer gel of refabrication 5% (960 μ l, 30% acrylamide soln, 740 μ l 1MTris/Cl PH6.8,60 μ l 10%SDS, 60 μ l, 10% ammonium persulfate, 5 μ l TEMED), on spacer gel, insert broach, treat that glue condenses fully after, pull up broach.

4) sample of will be above-mentioned handling well adds in the glue hole and carries out electrophoresis, first 20mA, 1h, 40mA then, 2h.

5) 100v, 1h forwards the albumen on the glue on the pvdf membrane to.

6) film that takes a turn for the better seals with 5% skim-milk, and 37 ℃, 1h.

7) wash film twice with 1xPBST.

8) film is immersed in the serum of dilution in 1: 500,4 ℃, spends the night.

9) discard serum, wash film 6 times, each 10min at interval with 1xPBST.

10) discard washing lotion, add the goat anti-rabbit igg of 1: 5000 dilution HPR mark, 37 ℃, 1h.

11) discard two and resist, wash film 6 times, each 10min at interval with 1xPBST.

12) luminous agent is added on the film, scotography.

The results are shown in Figure 5, Fig. 5 shows: detect specific antibody in the serum that can obtain after pJW4303-TcdA-C dna vaccination immunity New Zealand white rabbit, it is all reactionless that its apparent molecular weight is about supernatant, the cracking of 36kDa and these antibody and pJW4303 transfection.

The part that the present invention does not relate to prior art that maybe can adopt all same as the prior art is realized.

Related reagent information such as following table among the embodiment:

Taq enzyme Promega company

T4DNA ligase enzyme Promega company

The precious biotech firm in DNAmarker (DL 3000) Dalian

Restriction enzyme BamH I, Pst I and Sac I Fermentas company

Dna gel reclaims the precious biotech firm in test kit Dalian

DMEM high glucose medium Hyclone company

Foetal calf serum Gibico company

Plasmid extracts the precious biotech firm in test kit Dalian in a small amount

Plasmid extracts test kit Qiagen company in a large number

PEI Invitrogen company

The sheep anti-mouse igg SouthernBiotech company of HRP mark

The goat anti-rabbit igg SouthernBiotech company of HRP mark

TMB tablet Sigma company.

Sequence table

＜110〉Wang Shixia, Jin Ke, Huang Zuhu, Lu Shan

＜120〉codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence and nucleic acid vaccine thereof

<160>2

 

<210>1

<211>978

<212>DNA

＜213〉artificial sequence

<220>

＜223〉codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence

<400>1

atggccagca?ccggctacac?cagcatcaac?ggcaagcact?tctacttcaa?caccgacggc?60

atcatgcaga?tcggcgtgtt?caagggcccc?aacggcttcg?agtacttcgc?ccctgccaac?120

accgatgcca?acaacatcga?gggccaggcc?atcctgtacc?agaacaagtt?cctgaccctg?180

aacggcaaga?agtactactt?cggcagcgac?agcaaggctg?tgaccggcct?gcggaccatc?240

gacggcaaaa?agtattattt?caacaccaac?accgccgtgg?ccgtgacagg?ctggcagacc?300

atcaatggga?agaagtatta?ctttaatacc?aataccagca?ttgcctccac?cggctataca?360

atcatctccg?ggaagcactt?ttatttcaat?acagatggga?ttatgcagat?tggagtgttt?420

aaaggccctg?atggctttga?gtactttgct?cccgctaata?cagacgccaa?taatatcgaa?480

ggacaggcca?ttagatacca?gaaccgcttc?ctgtatctgc?acgacaacat?ctactacttt?540

ggcaacaact?ccaaggccgc?caccggctgg?gtgacaatcg?atggcaaccg?ctactacttc?600

gagcccaata?ccgccatggg?cgccaacggc?tacaagacca?tcgacaacaa?gaatttctac?660

ttccggaacg?gcctgcccca?gattggcgtc?tttaagggca?gcaatggatt?cgagtatttt?720

gccccagcaa?acactgatgc?taacaatatt?gaggggcagg?ctatcaggta?tcagaatcga?780

ttcctgcatc?tgctggggaa?gatctattac?ttcggcaata?atagcaaggc?tgtgactggg?840

tggcagacaa?ttaacggcaa?ggtgtactat?ttcatgcccg?acacagccat?ggccgctgcc?900

ggcggactgt?tcgagatcga?cggcgtgatc?tacttcttcg?gcgtggacgg?cgtgaaggcc?960

cctggcatct?acggctga???????????????????????????????????????????????978

 

<210>2

<211>978

<212>DNA

＜213〉clostridium difficile (Clostridium difficile)

<220>

＜223〉original clostridium difficile exotoxin A carboxy-terminal gene sequence

<400>2

atggcctcaa?ctggttatac?aagtattaat?ggtaaacatt?tttattttaa?tactgatggt?60

attatgcaga?taggagtgtt?taaaggacct?aatggatttg?aatactttgc?acctgctaat?120

acggatgcta?acaacataga?aggtcaagct?atactttacc?aaaataaatt?cttaactttg?180

aatggtaaaa?aatattactt?tggtagtgac?tcaaaagcag?ttaccggact?gcgaactatt?240

gatggtaaaa?aatattactt?taatactaac?actgctgttg?cagttactgg?atggcaaact?300

attaatggta?aaaaatacta?ctttaatact?aacacttcta?tagcttcaac?tggttataca?360

attattagtg?gtaaacattt?ttattttaat?actgatggta?ttatgcagat?aggagtgttt?420

aaaggacctg?atggatttga?atactttgca?cctgctaata?cagatgctaa?caatatagaa?480

ggtcaagcta?tacgttatca?aaatagattc?ctatatttac?atgacaatat?atattatttt?540

ggtaataatt?caaaagcggc?tactggttgg?gtaactattg?atggtaatag?atattacttc?600

gagcctaata?cagctatggg?tgcgaatggt?tataaaacta?ttgataataa?aaatttttac?660

tttagaaatg?gtttacctca?gataggagtg?tttaaagggt?ctaatggatt?tgaatacttt?720

gcacctgcta?atacggatgc?taacaatata?gaaggtcaag?ctatacgtta?tcaaaataga?780

ttcctacatt?tacttggaaa?aatatattac?tttggtaata?attcaaaagc?agttactgga?840

tggcaaacta?ttaatggtaa?agtatattac?tttatgcctg?atactgctat?ggctgcagct?900

ggtggacttt?tcgagattga?tggtgttata?tatttctttg?gtgttgatgg?agtaaaagcc?960

cctgggatat?atggctaa???????????????????????????????????????????????978

Claims (3)

1. codon optimized clostridium difficile exotoxin A carboxy-terminal gene sequence, sequence is SEQ ID NO.1.

2. clostridium difficile extracellular toxin nucleic acid vaccine is characterized in that this vaccine is made up of described clostridium difficile exotoxin A carboxy-terminal gene sequence of claim 1 and carrier for expression of eukaryon.

3. clostridium difficile extracellular toxin nucleic acid vaccine according to claim 2 is characterized in that described carrier for expression of eukaryon is pJW4303.

Images